PREVACID(R) (lansopraxole)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved April 1998

Specific Treatments:


General Information

TAP Holdings received approval from the U.S. Food and Drug Administration (FDA) for PREVACID(R) (lansoprazole) Delayed-Release Capsules in the short-term treatment of Symptomatic GERD. The most common symptom of GERD is heartburn caused by the reflux of gastric juices from the stomach into the esophagus.

Side Effects

PREVACID is well tolerated. The most frequently reported adverse events included headache, abdominal pain and diarrhea.